Chiarella Paula, Vulcano Marisa, Bruzzo Juan, Vermeulen Mónica, Vanzulli Silvia, Maglioco Andrea, Camerano Gabriela, Palacios Víctor, Fernández Gabriela, Brando Romina Fernández, Isturiz Martín A, Dran Graciela I, Bustuoabad Oscar D, Ruggiero Raúl A
Academia Nacional de Medicina de Buenos Aires, Pacheco de Melo 3081, 1425, Buenos Aires, Argentina.
Cancer Immunol Immunother. 2008 May;57(5):701-18. doi: 10.1007/s00262-007-0410-4. Epub 2007 Oct 26.
Although animals can be immunized against the growth of some tumor implants, most of the attempts to use immunotherapy to cause the regression of animal and human tumors once they have become established have been disappointing even when strongly immunogenic tumors were used as target. In this paper, we demonstrate that the failure to achieve an efficient immunological treatment against an established strongly immunogenic murine fibrosarcoma was paralleled with the emergence of a state of immunological unresponsiveness (immunological eclipse) against tumor antigens observed when the tumor surpassed the critical size of 500 mm(3). In turn, the onset of the immunological eclipse was coincidental with the onset of a systemic inflammatory condition characterized by a high number of circulating and splenic polymorphonucleated neutrophils (PMN) displaying activation and Gr1(+)Mac1(+) phenotype and an increasing serum concentration of the pro-inflammatory cytokines TNF-alpha, IL-1beta and IL-6 cytokines and C-reactive protein (CRP) and serum A amyloid (SAA) phase acute proteins. Treatment of tumor-bearing mice with a single low dose (0.75 mg/kg) of the synthetic corticoid dexamethasone (DX) significantly reduced all the systemic inflammatory parameters and simultaneously reversed the immunological eclipse, as evidenced by the restoration of specific T-cell-dependent concomitant immunity, ability of spleen cells to transfer anti-tumor activity and recovery of T-cell signal transduction molecules. Two other anti-inflammatory treatments by using indomethacin or dimeric TNF-alpha receptor, also partially reversed the immunological eclipse although the effect was not as striking as that observed with DX. The reversion of the immunological eclipse was not enough on its own to inhibit the primary growing tumor. However, when we used the two-step strategy of inoculating DX to reverse the eclipse and then dendritic cells loaded with tumor antigens (DC) as an immunization booster, a significant inhibition of the growth of both established tumors and remnant tumor cells after excision of large established tumors was observed, despite the fact that the vaccination alone (DC) had no effect or even enhanced tumor growth in certain circumstances. The two-step strategy of tumor immunotherapy that we present is based on the rationale that it is necessary to eliminate or ameliorate the immunological eclipse as a precondition to allow an otherwise ineffective anti-tumor immunological therapy to have a chance to be successful.
尽管动物可以针对某些肿瘤植入物的生长进行免疫,但大多数在动物和人类肿瘤形成后使用免疫疗法使其消退的尝试都令人失望,即便使用强免疫原性肿瘤作为靶点也是如此。在本文中,我们证明,对于已形成的强免疫原性小鼠纤维肉瘤未能实现有效的免疫治疗,这与当肿瘤超过500立方毫米的临界大小时所观察到的针对肿瘤抗原的免疫无反应状态(免疫失能)的出现是平行的。反过来,免疫失能的开始与一种全身性炎症状态的开始同时发生,其特征是大量循环和脾脏中的多形核中性粒细胞(PMN)呈现激活状态且具有Gr1(+)Mac1(+)表型,以及促炎细胞因子TNF-α、IL-1β和IL-6细胞因子以及C反应蛋白(CRP)和血清淀粉样蛋白A(SAA)等急性期蛋白的血清浓度不断升高。用单剂量低剂量(0.75毫克/千克)的合成皮质类固醇地塞米松(DX)治疗荷瘤小鼠,显著降低了所有全身炎症参数,同时逆转了免疫失能,这表现为特异性T细胞依赖性伴随免疫的恢复、脾细胞转移抗肿瘤活性的能力以及T细胞信号转导分子的恢复。使用吲哚美辛或二聚体TNF-α受体进行的另外两种抗炎治疗,也部分逆转了免疫失能,尽管效果不如DX显著。免疫失能的逆转本身并不足以抑制原发性生长肿瘤。然而,当我们采用两步策略,即接种DX以逆转免疫失能,然后用负载肿瘤抗原的树突状细胞(DC)作为免疫增强剂时,尽管单独接种疫苗(DC)在某些情况下没有效果甚至会促进肿瘤生长,但观察到对已形成的肿瘤以及大的已形成肿瘤切除后的残留肿瘤细胞的生长有显著抑制作用。我们提出的肿瘤免疫治疗两步策略基于这样的基本原理,即有必要消除或改善免疫失能,以此作为使原本无效的抗肿瘤免疫治疗有机会取得成功的前提条件。